Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Houston, Texas 77030


Phase II trial to study the effectiveness of oxaliplatin in treating patients who have relapsed or refractory non-Hodgkin's lymphoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

Study summary:

OBJECTIVES: I. Determine the response rate to oxaliplatin in patients with relapsed or refractory non-Hodgkin's lymphoma. II. Determine the treatment-related toxicity of this drug in these patients. OUTLINE: This is a multicenter study. Patients are stratified according to histologic subtype (indolent vs aggressive). Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A maximum of 72 patients will be accrued for this study within 2-3 years.


Inclusion Criteria: - Histologically or cytologically confirmed recurrent or refractory non-Hodgkin's lymphoma (NHL) of any histologic subtype - Indolent - Follicular small cleaved cell - Follicular mixed cell - Small lymphocytic - Mucosa-associated lymphoid tissue (MALT) - Monocytoid B-cell - Waldenstrom's macroglobulinemia - Aggressive - Follicular large cell - Diffuse large cell - Immunoblastic - Mantle cell - Ki-1+ NHL - Peripheral T-cell - Angiocentric and angioimmunoblastic - Transformed lymphoma - Bidimensionally measurable disease - No more than 3 prior treatment regimens as follows: - Primary radiotherapy is 1 regimen - Combined therapy with radiotherapy and chemotherapy is 1 regimen - Alternating therapy is 1 regimen - No known brain metastases - Performance status - ECOG 0-2 - Performance status - Karnofsky 50-100% - WBC count at least 3,000/mm^3 - Absolute neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 - Bilirubin normal - SGOT/SGPT no greater than 2.5 times upper limit of normal - Creatinine normal - Creatinine clearance at least 60 mL/min - No symptomatic congestive heart failure - No unstable angina pectoris - No cardiac arrhythmia - No neuropathy greater than grade 1 - No history of allergy to platinum compounds or antiemetics - No uncontrolled illness - No active infection - Not pregnant or nursing - Fertile patients must use effective contraception - No concurrent colony-stimulating factors during first course of therapy - At least 4 weeks since prior chemotherapy - At least 4 weeks since prior radiotherapy - No other concurrent investigational drugs - No concurrent antiretroviral therapy for HIV-positive patients



Primary Contact:

Principal Investigator
Anas Younes
M.D. Anderson Cancer Center

Backup Contact:


Location Contact:

Houston, Texas 77030
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: December 02, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.